Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 12
Submit an article Journal homepage
1,449
Views
72
CrossRef citations to date
0
Altmetric
Reviews

Recent advances in intravenous delivery of poorly water-soluble compounds

Yi Shi Department R43D, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064-6196, USA
, PhD,
William Porter Department R4P3, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064-6120, USA+1 847 937 1770; +1 847 935 1889;
, PhD,
Thomas Merdan Scientific Project Management, Abbott GmbH & Co. KG, Global Pharmaceutical, Research & Development, SOLIQS, Knollstrasse, 67061 Ludwigshafen, Germany
, PhD &
Luk Chiu Li Abbott Animal Health, Department AH71, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064-6375, USA
, PhD
Pages 1261-1282 | Published online: 26 Nov 2009

Bibliography

  • Timpe C. Strategies for formulating development of poorly water-soluble drug candidates – a recent perspective. Am Pharm Rev 2007;0(3):104-9
  • Liu R. Water insoluble drug formulation, 2nd edition, Boca Raton, FL: CRC Press, Taylor & Francis Group; 2008
  • Duma RJ, Akers MJ, Turco SJ. Parenteral drug administration: routes, precautions, problems, complications, and drug delivery systems, chapter 2. In: Avis KE, Lieberman HA, Lachman L, editors, Pharmaceutical dosage forms: parenteral medications, 2nd edition New York NY: Marcel Dekker, Inc.; 1992. p. 17-58
  • Duma RJ, Akers MJ, Turco SJ. Particulate matter in injections. USP 32-NF 27 S1 <788>, Rockville, MD: United States Pharmacopeia; 2009
  • DeLuca PP, Boylan JC. Formulation of small volume parenterals, chapter 5. In: Avis KE, Lieberman HA, Lachman L, editors, Pharmaceutical dosage forms: parenteral medications. 2nd edition. New York NY: Marcel Dekker, Inc.; 1992. p. 173-248
  • Yalkowsky SH. Solubility and solubilization in aqueous media. Washington, D.C.: American Chemical Society; 1999
  • Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30
  • Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-51
  • Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15-30
  • Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18-28
  • Al-Soufi W, Cabrer PR, Jover A, Determination of second-order association constants by global analysis of 1H and 13C NMR chemical shifts. Application to the complexation of sodium fusidate and potassium helvolate by beta- and gamma-cyclodextrin. Steroids 2003;68:43-53
  • Liu Y, Chen GS, Chen Y, Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis(beta-cyclodextrin)s: solubilization and antitumor activity. Bioorg Med Chem 2004;12:5767-75
  • Wen X, Liu Z, Zhu T, Evidence for the 2:1 molecular recognition and inclusion behaviour between beta- and gamma-cyclodextrins and cinchonine. Bioorg Chem 2004;32:223-33
  • Vargas-Berenguel A, Ortega-Caballero F, Santoyo-Gonzalez F, Dendritic galactosides based on a beta-cyclodextrin core for the construction of site-specific molecular delivery systems: synthesis and molecular recognition studies. Chemistry 2002;8:812-27
  • Kolhe P, Misra E, Kannan RM, Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143-60
  • Boas U, Sontjens SH, Jensen KJ, New dendrimer peptide host guest complexes: towards dendrimers as peptide carriers. Chembiochem 2002;3:433-9
  • Kannan S, Kolhe P, Raykova V, Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed 2004;15:311-30
  • Fuchs S, Otto H, Jehle S, Fluorescent dendrimers with a peptide cathepsin B cleavage site for drug delivery applications. Chem Commun (Camb) 2005;1830-2
  • Patri AK, Kukowska-Latallo JF, Baker JR Jr Targeted drug delivery with dendrimers. comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005;57:2203-14
  • Dhanikula RS, Hildgen P. Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery. Bioconjug Chem 2006;17:29-41
  • Bermejo JF, Ortega P, Chonco L, Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007;13:483-95
  • SoluBestWater soluble nanoparticles inclusion complexes. WO2005030257; 2005
  • Halford B. Molecules get suited up. Chem Eng News 2006;84(42):11
  • Hussain R, Siligardi G. Fat-free albumin as a novel drug delivery system. Int J Peptide Res Ther 2006;2(3):311-15
  • Wunder A, Müller-Ladner U, Stelzer EH, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003;170:4793-801
  • Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8
  • Ten Tije AJ, Verweij J, Loos WJ, Sparreboon A. Pharmacological effects of formulation vehicles: Implications for cancer chemotheraphy. Clin Pharmacokinet 2003;42(7):665-85
  • Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006;112:630-48
  • Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Exp Opin Drug Deliv 2006;3(1):139-62
  • Torchilin VP. Block copolymer micelles as a solution for drug delivery problems. Expert Opin Ther Patents 2005;15(1):63-75
  • Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002;54:169-90
  • Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003;92:1343-55
  • Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82(2-3):189-212
  • Le GD, Gori S, Luo L, Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004;99:83-101
  • Benahmed A, Ranger M, Leroux JC. Novel polymeric micelles based on the amphiphilic diblock copolymer poly(N-vinyl-2-pyrrolidone)-block-poly(D,L-lactide). Pharm Res 2001;18:323-8
  • Gaucher G, Dufresne MH, Sant VP, Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005;109:169-88
  • Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 2002;15:115-33
  • Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002;19:1-72
  • Kozlov MY, Milik-Nubarov NS, Batrakova EV, Kabanov AV. Relationship between Pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes. Macromolecules 2000;33:3305-13
  • Meadows JSynergistic mixed Poloxamers for the solubilization of drugs. US20040258718A1; 2004
  • Danson S, Ferry D, Alakhov V, Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004;90:2085-91
  • Allen C, Han J, Yu Y, Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J Control Release 2000;63:275-86
  • Leung SY, Jackson J, Miyake H, Polymeric micellar paclitaxel phosphorylates Bcl 2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 2000;44:156-63
  • Kim TY, Kim DW, Chung JY, Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16
  • Park SR, Oh DY, Kim DW, A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004;12:1059-64
  • Matsumura Y, Hamaguchi T, Ura T, Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004;91:1775-81
  • Hamaguchi T, Matsumura Y, Suzuki M, NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005;92:1240-6
  • Nakanishi T, Fukushima S, Okamoto K, Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001;74:295-302
  • Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 2002;9:1424-9
  • Maeda H, Wu J, Sawa T, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
  • Liu SQ, Wiradharma N, Gao SJ, Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007;28:1423-33
  • Soga O, Van Nostrum CF, Fens M, Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005;103:341-53
  • Lee ES, Shin HJ, Na K, Bae YH. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release 2003;90:363-74
  • Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007;118:216-24
  • Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 2006;62:235-40
  • Lukyanov AN, Gao Z, Torchilin VP. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003;91:97-102
  • Park EK, Kim SY, Lee SB, Lee YM. Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005;109:158-68
  • Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004;96:273-83
  • Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-96
  • Mouton JW, Van Peer A, De Beule K, Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006;50:4096-102
  • Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318
  • Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004;284:109-22
  • Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-20
  • Moschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615-19
  • Wong J, Brugger A, Khare A, Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008;60:939-54
  • Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43-8
  • Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3-16
  • Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19
  • Müller RH, Benita S, Böhm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart, Germany: Medpharm Scientific Publishers; 1998
  • DissoCubes. SkyePharma PLC, London, UK, 2008. Available from: www.skyepharma.com/technology/oral technology/particle engineering technologies/dissocubes.html [Last accessed 9 March 2009]
  • Baxter International Microprecipitation method for preparing submicron suspensions. US6607784; 2003
  • Asahi T, Masuhara H, Sugiyama T, . Process for producing fullerene dispersion liquid, and fullerene dispersion liquid. EP1939140A1; 2008
  • Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci 2007;30:367-74
  • Nanomorph®: Introduction. SOLIQS, Abbott Gmbh & Co., KG, Ludwigshafen, Germany Available from: www.soliqs.com/NanoMorph R.20.0.html [Last accessed 9 March 2009]
  • Lindfors L, Skantze P, Skantze U, Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 2007;23:9866-74
  • ABRAXANE® (paclitaxel albumin-bound particles) for Injectable Suspension prescription information. Abraxis BioScience, LLC, Los Angeles, CA, 2008 Available from: www.abraxane.com [Last accessed 9 March 2009]
  • Desai NP, Soon-Shiong P, Magdassi S, Sahadevan DCNovel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof. WO9900113; 1999
  • Bristow S, Shekunov T, Shekunov B. Analysis of the supersaturation and precipitation process with supercritical CO2. J Supercrit Fluids 2001;21(3):257-71
  • Shekunov BY, Chattopadhyay P, Seitzinger J, Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006;23:196-204
  • Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Sci 2006;27:299-310
  • Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-86
  • Gassmann P, List M, Schweitzer A, Sucker H. Hydrosols: alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm 1994;40(22):64-72
  • Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci 2007;0(5):367-74
  • Peters K, Müller RH, Craig DQ. An investigation into the distribution of lecithins in nanosuspension systems using low frequency dielectric spectroscopy. Int J Pharm 1999;184:53-61
  • Ostwald W. Studies on the formation and inversion of solids. First paper: supersaturation and supercooling. Z Physik Chemie 1897;22:289-330
  • Lindfors L, Skantze P, Skantze U, Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 2006;22:906-10
  • Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release 2006;111:185-92
  • Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Path 2008;36:43-8
  • Rabinow B, Kipp J, Papadopoulos P, Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339(1-2):251-60
  • Davis SS, Washington C, West P, Lipid emulsions as drug delivery systems. Ann NY Acad Sci 1987;507:75-88
  • Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-40
  • ABELCET. Enzon Pharmaceuticals, Inc., Bridgewater, NJ, 2008. Available from: www.enzon.com/index.php?id=35 [Last accessed 9 March 2009]
  • Fahr A, Van HP, May S, Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-65
  • Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003;4:1277-87
  • Visudyne. Novartis Pharmaceuticals Corp., East Hanover, N, 2008. Available from: www.visudyne.com/info/visudyne/visudyne.jsp [Last accessed 9 March 2009]
  • Von Roenn JH, Lee S, Cianfrocca M, Phase III study of paclitaxel (Pac) versus pegylated liposomal doxorubicin (PLD) for the treatment of advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS): an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):, 20503aa
  • Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. U.S. national Institutes of health, Bethesda, MD, 2009 Available from: clinicaltrials.gov/ct2/show/NCT00344422?intr=%22Dexamethasone%22&rank=9 [Last accessed 9 March 2009]
  • Booser DJ, Esteva FJ, Rivera E, Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 2002;50(1):6-8
  • Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975;394:483-91
  • Segarra I, Movshin Da L, Zarif L. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J Pharm Sci 2002;91(8):1827-37
  • FluidCrystal® NP Injection nanoparticles. CAMURUS AB, Lund, Sweden, 2009 Available from: camurus.verkstad.org/index.asp?DocumentID=3&DocumentIDSub=8&Lang=&ShowSub=(2)&Show=(3) &main=Technologies [Last accessed 9 March 2009]
  • Johnsson M, Barauskas J, Norlin A, Tiberg F. Physicochemical and drug delivery aspects of lipid-based liquid crystalline nanoparticles: a case study of intravenously administered propofol. J Nanosci Nanotechnol 2006;6:3017-24
  • Hemenway J, Stella VJ. Prodrugs and parenteral drug delivery (2.2.2). In: Stella, ., editors, Prodrugs: challenges and rewards, Part I New York, NY: AAPS Press, Springer Science + Business Media, LLC; 2007. p. 218-81
  • Johnsson M, Barauskas J, Tiberg F. Cubic phases and cubic phase dispersions in a phospholipid-based system. J Am Chem Soc 2005;127:1076-7
  • Barauskas J, Johnsson M, Joabsson F, Tiberg F. Cubic phase nanoparticles (Cubosome): principles for controlling size, structure, and stability. Langmuir 2005;21:2569-77
  • Ishikawa T, Matsunaga N, Tawada H, TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-37
  • Detoledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000;22(6):459-66
  • Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42:33-58
  • Fechner J, Ihmsen H, Hatterscheid D, Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003;99:303-13
  • Ueda Y, Matiskella JD, Golik J, Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg Med Chem Lett 2003;13:3669-72
  • Hanson BA. Evaluation of a phosphoryloxymethyl (POM) prodrug of camptothecin: Preformulation, formulation and pharmacokinetic studies. Ph.D. Dissertation, University of Kansas; 2002;181
  • Hanson BA, Schowen RL, Stella VJ. A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm Res 2003;20:1031-8
  • Liu X, Lynn BC, Zhang J, A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc 2002;124(26):7650-1
  • Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-23
  • Takata J, Hidaka R, Yamasaki A, Novel d-gamma-tocopherol derivative as a prodrug for d-gamma-tocopherol and a two-step prodrug for S-gamma-CEHC. J Lipid Res 2002;43:2196-204
  • Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
  • Vicent MJ. Polymer drug conjugates as modulators of cellular apoptosis. AAPS J 2007;9(2):E200-7
  • Vasey PA, Kaye SB, Morrison R, Phase I clinical and pharmacokinetics study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents drug polymer conjugates. Clin Cancer Res 1999;5:83-94
  • Duncan R. N-(2-hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon, editor, Polymeric drug delivery systems, New York, NY: Marcel Dekker; 2005. p. 1-92
  • Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in caner therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006;5:1909-17
  • Ducan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701
  • Rowinsky EK, Rizzo J, Ocho L, A phase I and pharmacokinetic study of camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003;21:148-57
  • Scott L, Evans T, Uao J, Pegamotecan (EZ-246) a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a sing-agent phase-2 study. J Clin Oncol 2004;22(14S):4030
  • Bhatt R, De Vries P, Tulinsky J, Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin. J Med Chem 2003;46:190-3
  • Singer JW, Bhatt R, Tulinsky J, Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-7
  • Singer JW, De Vries P, Bhatt R, Conjugation of camptothecin to poly-(L-glutamic acid). Ann NY Acad Sci 2000;922:136-50
  • Singer J, Baker B, De Vries P, . Poly-(L)-Glutamic acid-paclitaxel (CT-2103) [XYOTAX®], a biodegradable polymeric drug conjugate. Characterization, preclinical pharmacology, and preliminary clinical data. In: Maeda, . editors, Polymer drugs in the clinical stage advantages and prospects, New York NY: Kluwer Academic/Plenum Publishers; 2003. p. 81-99
  • Auzenne E, Donato NJ, Li C, . Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian caricinoma. Clin Cancer Res 2002;8:573-81
  • Skwarczynski M, Kiso Y. Application of the O–N intramolecular acyl migration reaction in medicinal chemistry. Curr Med Chem 2007;14:2813-23
  • Hayashi Y, Skwarczynski M, Hamada Y, . A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. J Med Chem 2003;46:3782-4
  • Agalloco JP. Thinking inside the box: the application of isolation technology for aseptic processing. Pharm Technol 2006;30:8-11
  • Yang G, Jain N, Yalkowsky SH. Combined effect of SLS and (SBE)(7M)-beta-CD on the solubilization of NSC-639829. Int J Pharm 2004;269:141-8
  • Tommasini S, Calabro ML, Raneri D, Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin. J Pharm Biomed Anal 2004;36:327-33
  • Gladys G, Claudia G, Marcela L. The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin. Eur J Pharm Sci 2003;20:285-93
  • Basavaraj S, Sihorkar V, Shantha Kumar TR, Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxypropyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component. Pharm Dev Technol 2006;11:443-51
  • Valero M, Perez-Revuelta BI, Rodriguez LJ. Effect of PVP K-25 on the formation of the naproxen:beta-ciclodextrin complex. Int J Pharm 2003;253:97-110
  • Cirri M, Maestrelli F, Corti G, Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. J Pharm Biomed Anal 2006;42:126-31
  • Granero G, De Bertorello MM, Longhi M. Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD. Boll Chim Farm 2002;141:63-6
  • Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJ. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. Eur J Pharm Sci 2005;24:1-13
  • AI 850™ Our reformulation of paclitaxel and potential bioequivalent of Abraxane®. Acusphere, Inc., Watertown, MA, 2008 Available from: www.acusphere.com/product/prod_ai850.html [Last accessed 9 March 2009]
  • Straub JA, Chickering DE, Lovely JC, Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res 2005;22:347-55
  • Straub JA, Chickering DE, Lovely JC, . Technology: the process particle formation and nanoparticles. CritiTech, Inc., Lawrence KS, 2007. Available from: www.crititech.com/technology.html [Last accessed 9 March 2009]
  • Straub JA, Chickering DE, Lovely JC, . Improving the clinical performance of drugs. Thar Pharmaceuticals, Inc., Pittsburgh, PA, 2008. Available from: www.tharpharma.com/index.htm [Last accessed 9 March 2009]
  • Telesso Technologies Limited, North Ryde NSW, Australia, 2008 Available from: http://telesso.com/ [Last accessed 9 March 2009]
  • Bioral® Technology. BioDelivery Sciences International, Raleigh, NC, 2009. Available from: www.biodeliverysciences.com/Bioral.php [Last accessed 9 March 2009]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.